Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 5, 2006, Pages 247-255

  Sasaki, Takamitsu ^a   Masubuchi, Akiko ^a   Yamamura, Mayumi ^b   Watanabe, Nobuaki ^b   Hiratsuka, Masahiro ^a   Mizugaki, Michinao ^a   Itoh, Kunio ^a   Tanaka, Yorihisa ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Aldehyde oxidase; MAO A inhibitor; Rat; RS 8359; Stereoselectivity; Strain differences

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; ALDEHYDE OXIDASE; HYDROCORTISONE; MESSENGER RNA; MONOAMINE OXIDASE A INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL FRACTIONATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG OXIDATION; ENZYME ACTIVITY; GENE EXPRESSION; HEREDITY; LIVER CYTOSOL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RAT STRAIN; STEREOSPECIFICITY; STRAIN DIFFERENCE;

ALDEHYDE OXIDASE; ANIMALS; BLOTTING, NORTHERN; CATALYSIS; CYTOSOL; LIVER; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; NITRILES; OXIDATION-REDUCTION; PYRIMIDINES; RATS; RATS, INBRED STRAINS; RNA, MESSENGER; STEREOISOMERISM;

EID: 33746456808     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.504     Document Type: Article

References (36)

1. Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J Pharm Pharmacol 1989; 41: 32-36.
2. Kumagae Y, Matsui Y, Iwata N. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 1991; 55: 121-128.
3. Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. J Neural Transm 1993; 94: 175-187.
4. Iwata N, Tonohiro T, Kozuka M, Kumagae Y, Takasaki W, Tanaka Y. A novel selective and reversible MAO-A inhibitor, RS-8359: its pharmacological properties and metabolism. Int Acad Biomed Drug Res 1996; 11: 285-286.
5. Puchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharm 1997; 12: S17-S23.
6. Plenker A, Puchler K, Volz HP, The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. Int Clin Psychopharm 1997; 12: S25-S29.
7. Iwabuchi H, Takasaki W, Kuwano H, Kobayashi T, Tanaka Y. Structural determination of rat and dog urinary metabolites of a new antidepressant RS-8359. Xenobio Metab Dispos 1998; 13: 351-361.
8. Takasaki W, Yamamura M, Shigehara E, et al. Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-type monoamine oxidase, in rats, mice, dogs, and monkeys. Biol Pharm Bull 1999; 22: 498-503.
9. Takasaki W, Yamamura M, Nozaki A, et al. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug metabolizing enzymes. Chirality 2005; 17: 135-141.
10. Itoh K, Yamamura M, Muramatsu. S, et al. Stereospecific oxidation of (S)-enantiomer of RS-8359, a selective and reversible MAO-A inhibitor, by aldehyde oxidase. Xenobiotica 2005; 35: 561-573.
11. Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, Tanaka Y. Species differences in enantioselective 2-oxidation of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 2006; 27: 133-139.
12. Beedham C. Molybdenum hydroxylase. In Enzyme Systems that Metabolise Drug and Other Xenobiotics, Ioannides C (ed.). John Wiley: Chichester, UK, 2002; 147-187.
13. Rajagopalan KV. Xanthine oxidase and aldehyde oxidase. In Enzymatic Basis of Detoxication, Jacoby WB (ed.). Academic Press: London, 1990; 295-309.
14. Beedham C. Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 1985; 16: 119-156.
15. Beedham C. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity. Prog Med Chem 1987; 24: 85-121.
16. Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci 1997; 19: 255-263.
17. DeMiranda P, Good SS. Species differences in the metabolism and disposition of antiviral nucleoside analogues: Acyclovir. Antivir Chem Chemo 1992; 3: 1-8.
18. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metab Dispos 1997; 25: 805-813.
19. Jordan CGM, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea pig, rabbit and man. J Pharm Pharmacol 1999; 51: 411-418.
20. Kitamura S, Sugihara K, Nakatani K, et al. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. UBMB Life 1999; 48: 607-611.
21. Beedham C, Al-Tayib Y, Smith JA. Role of guinea pig and rabbit hepatic aldehyde oxidase in the oxidative in vitro metabolism of cinnchona alkaloids. Drug Metab Dispos 1992; 20: 889-895.
22. Wanwimolruk S, Wong SM, Zhang H, Coville PF, Walker RJ. Metabolism of quinine in man: Identification of a major metabolite, and effects of smoking and rifampicin treatment. J Pharm Pharmacol 1995; 47: 957-963.
23. Sugihara K, Katsuma Y, Kitamura S, Ohta S, Fujitani M, Shintani H. Cynomolgus monkey liver aldehyde oxidase: extremely high oxidase activity and an attempt at purification. Comp Biochem Physiol C 2000; 126: 53-60.
24. Beedham C, Bruce SE, Critchley DJ, Al-Tayib Y, Rance DJ. Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 1987; 12: 307-310.
25. Beedham C, Critchley DJP, Rance DJ. Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit and baboon. Arch Biochem Biophys 1995; 319: 481-490.
26. Chaudhary I, DeMario W, Kantrowitz J. Species comparison of in vitro and in vivo metabolism of CL284,846, a non-benzodiazepine sedative/hypnotic agent. Pharm Res 1994; 11: 319.
27. Acheampong AA, Chien D-S, Lam S, et at. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 1996; 26: 1035-1055.
28. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, Watabe T. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkey and rats. Drug Metab Dispos 1999; 27: 422-428.
29. Schofield PC, Robertson IGC, Paxton JW. Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol 2000; 59: 161-165.
30. Austin NE, Baldwin SJ, Cutler L, et al. Pharmacokinetics, of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey. in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001; 31: 677-686.
31. Kitamura S, Nakatani K, Sugihara K, Ohta S. Strain differences of the ability to hydroxylate methotrexate in rats. Camp Biochem Physiol C 1999; 122: 331-336.
32. Sugihara K, Kitamura S, Tatsumi K. Strain differences of liver aldehyde oxidase activity in rat. Biochem Mol Biol Int 1995; 37: 861-869.
33. Kunieda T, Kobayashi E, Tachibana M, Ikada H. A genetic linkage map of rat chromosome 9 with a new locus for variant activity of liver aldehyde oxidase. Exp Anim 1999; 48: 43-45.
34. 1-methylnicofinamide and pyridoxal. Arch Biochem Biophys 1971; 145: 27-34.
35. Al-Salmy HS. Inter-strain variability in aldehyde oxidase activity in the mouse. Comp Biochem Physiol C 2002; 132: 341-347.
36. Tayama K, Fujii T, Hiraga K. Comparison of characteristics between F344 and Slc/Wistar rats - Slc/Wistar rats cannot be distinguished from the F344 strain. Jikken Dobutsu 1986; 35: 65-76.